EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
EQS-News: Eckert Ziegler SE
/ Key word(s): Alliance/Miscellaneous
June 19, 2024 – Berlin, Germany and Řež, Czech Republic – Eckert Ziegler Radiopharma GmbH (Eckert Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated yesterday with an official ceremony featuring Czech Prime Minister Petr Fiala, marks the culmination of a longstanding partnership between Eckert Ziegler and UJF. The facility is now close to operational readiness, and after additional testing, commercial production is slated to commence at the beginning of Q3/2024.
Currently, Ac-225-based radiopharmaceuticals are under clinical investigation for various cancers, including prostate tumors, colorectal cancer, and leukemia. A substantial increase in the demand for Ac-225 is projected over the next decade, driven by its expanding clinical applications and the promising results seen in ongoing trials. Despite its therapeutic promise, sufficient quantities of Ac-225 remain scarce. "Eckert Ziegler, in conjunction with UJF, has explored one of the most promising cyclotron-based production pathways for Ac-225," said Dr. Lutz Helmke, Managing Director of Eckert Ziegler Radiopharma GmbH. "Our collaboration signifies a major leap forward in isotope production, addressing the critical shortage of this isotope poised to revolutionize modern oncology." The newly inaugurated laboratory will leverage cutting-edge technologies, including a customized production line provided by Isotope Technologies Dresden GmbH, which represents the Plant Engineering business of Eckert Ziegler. Radium-226, necessary for irradiation processes, will also be supplied by Eckert Ziegler. "Today's opening marks a significant achievement in our collaboration with Eckert Ziegler," commented Prof. Ondřej Lebeda, Head of Department of Radiopharmaceuticals at UJF. "This new facility is a testament to our joint dedication to innovation in the therapeutic landscape for many cancer patients." Actinium-225 has emerged as a highly promising agent in the targeted therapy of small tumors and metastases. Its high-energy cascade of alpha particles with short penetration depths allows for precise targeting of tumor cells, including difficult-to-reach micro metastases, while minimizing impact on surrounding healthy tissue. About Eckert Ziegler Eckert Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives. About UJF The Nuclear Physics Institute of the Czech Academy of Sciences is a public research institution that conducts research in a broad field of nuclear physics, both experimental and theoretical. Its Department of radiopharmaceuticals focuses on the investigation and production of novel medical radionuclides as well as radionuclides important for physical research. Contact Eckert Ziegler SE Robert-Rössle-Str. 10, 13125 Berlin, Germany Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations [email protected] / [email protected] Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
19.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler SE |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1928009 |
End of News | EQS News Service |
|
1928009 19.06.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie genießt klare Unterstützung: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Die Community prognostiziert für Eckert & Ziegler Strahlen- und Medizintechnik AG ein Kursziel von 95 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 40.36 € bedeutet.